Literature DB >> 29978677

Australian Senate Committee Report on Transvaginal Mesh Devices.

Chloe Thompson1, Thomas Faunce2.   

Abstract

On 28 March 2018 the Australian Senate Community Affairs References Committee issued its final report on transvaginal mesh devices. It found these devices have caused unnecessary physical and emotional pain and suffering to thousands of women who were not told by their doctors of the objective material risks associated with their use. The Senate Committee concurred with the description by the Public Health Association of Australia of the complications resulting from transvaginal mesh implants as constituting a serious public health issue requiring a response at both an individual and at a population level, including counselling, public education, clinical interventions and long-lasting protective mechanisms. The committee's inquiry highlighted significant shortcomings in Australia's reporting systems for medical devices, with flow-on consequences for the health system's ability to respond in a timely and effective way. Among other recommendations, the Senate Committee backed the establishment on a cost recovery basis of a national registry of high-risk implantable devices linked to a system of mandatory reporting of adverse events.

Entities:  

Keywords:  Senate Committee; adverse events; fiduciary duty; transvaginal mesh

Mesh:

Year:  2018        PMID: 29978677

Source DB:  PubMed          Journal:  J Law Med        ISSN: 1320-159X


  2 in total

Review 1.  A review of gynaecological surgical practices for trainees and certified specialists in Australia by volume using MBS and AIHW databases.

Authors:  Lalla McCormack; Erin Nesbitt-Hawes; Rebecca Deans; Anais Alonso; Claire Lim; Fiona Li; Blake Knapman; Jason A Abbott
Journal:  Aust N Z J Obstet Gynaecol       Date:  2022-04-26       Impact factor: 1.884

2.  Women's Experiences of and Perspectives on Transvaginal Mesh Surgery for Stress Urine Incontinency and Pelvic Organ Prolapse: A Qualitative Systematic Review.

Authors:  Mina Motamedi; Stacy M Carter; Chris Degeling
Journal:  Patient       Date:  2021-10-05       Impact factor: 3.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.